Xcout IntelAvalon GloboCare Corp.
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
Subscribe to see Avalon GloboCare Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Avalon GloboCare Corp. at a glance
Avalon GloboCare Corp. is a biotech company headquartered in Freehold, United States. It is publicly listed (ALBT) with a market capitalisation of $923,171. Xcout tracks 19 named people at Avalon GloboCare Corp., including Meng Li (Interim CEO, COO & Secretary).
Avalon GloboCare Corp. leadership
- Meng LiInterim CEO, COO & Secretary
- Samuel J. KnipperChief Financial Officer
- Luisa IngargiolaChief Strategy Officer
- Luisa IngargiolaExecutive Officer
- Meng LiExecutive Officer
- David JinDirector
13 more named people on record for Avalon GloboCare Corp., with roles, board committees and tenure — see the full roster →
Avalon GloboCare Corp. competitors
A few of Avalon GloboCare Corp.'s closest competitors — see the full list of competitors and alternatives →
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
AGC Biologics is a global contract development and manufacturing organization (CDMO) that provides services for protein-based biologics and advanced therapies, including mammalian and microbial production, viral vectors, cell therapy, plasmid DNA, and mRNA. The company supports biopharmaceutical developers by offering process development, analytical formulation, cGMP manufacturing, and fill-finish services to help bring life-changing treatments to market.
AbelZeta is a global clinical-stage biopharmaceutical company pioneering T cell-based therapies targeting cancer, inflammation, and immunological issues, with centers in Rockville, Maryland and Shanghai, China.
Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to reduce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.
Get Avalon GloboCare Corp.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Avalon GloboCare Corp. in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access